Artivion (NYSE:AORT) Posts Quarterly Earnings Results

Artivion (NYSE:AORT) announced its earnings results on Thursday. The company reported $0.13 earnings per share for the quarter, FiscalAI reports. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million.

Here are the key takeaways from Artivion’s conference call:

• Q2 revenue increased 9% year over year to $125.8 million, while adjusted EBITDA rose 7% to $26.4 million. Stent graft revenue accelerated 12% and On-X revenue grew 18%, both despite tougher comparisons.
• Artivion received FDA PMA approval for AMDS in June, removing IRB-related hurdles and expanding permitted marketing claims; management expects adoption and U.S. account conversions to accelerate gradually in the second half rather than through an immediate surge.
• The company completed its Endospan acquisition and plans a full U.S. launch of the FDA-approved NEXUS aortic arch system in January 2027. Management views NEXUS, AMDS, On-X, and the ARTIZEN pipeline as collectively representing roughly $430 million in current U.S. market opportunity.
• Artivion reiterated 2026 guidance for 7%–11% constant-currency revenue growth, or $480 million–$496 million, and adjusted EBITDA of $92 million–$99 million. The outlook assumes minimal NEXUS revenue this year, continued preservation-services timing and supply constraints, and roughly $8 million of Endospan-related expenses.
• Free cash flow was negative $12 million in Q2, while net leverage rose to 3.1 following $150 million of borrowing to fund the Endospan acquisition; the company also expects the $25 million AMDS milestone payment in Q3 and remains exposed to manufacturing and geopolitical risks tied to Endospan’s Israel facility.

Artivion Price Performance

AORT traded up $0.63 on Friday, reaching $27.20. 1,081,660 shares of the company’s stock were exchanged, compared to its average volume of 597,567. The stock has a market cap of $1.32 billion, a PE ratio of -388.50 and a beta of 1.25. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The stock’s fifty day moving average price is $23.52 and its 200-day moving average price is $31.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Friday, April 10th. Canaccord Genuity Group set a $39.00 price objective on Artivion in a report on Friday. Weiss Ratings cut Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $44.67.

Insider Transactions at Artivion

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. Invesco Ltd. grew its stake in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Artivion by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after buying an additional 317,518 shares during the period. Two Sigma Investments LP lifted its holdings in Artivion by 235.5% in the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after acquiring an additional 313,446 shares during the last quarter. Loomis Sayles & Co. L P grew its position in Artivion by 35.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 840,062 shares of the company’s stock worth $38,315,000 after acquiring an additional 217,860 shares during the period. Finally, Voloridge Investment Management LLC grew its position in Artivion by 442.9% in the third quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock worth $9,318,000 after acquiring an additional 179,541 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Artivion reported second-quarter revenue of $125.8 million, up 11% year over year and above the approximately $120 million consensus estimate. Non-GAAP earnings were $0.13 per share, matching expectations, while adjusted EBITDA rose 7% to $26.4 million. Artivion Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, a regulatory milestone that could expand its aortic surgery product opportunity. Artivion also completed its acquisition of Endospan Ltd., potentially strengthening its portfolio and long-term growth prospects. Artivion Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Conestoga Capital Advisors highlighted Artivion as a long-term growth opportunity amid improving investor interest in small-cap stocks. The firm’s comments provide supportive institutional sentiment, although they do not represent a new price target or recommendation. Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges
• Neutral Sentiment: Artivion maintained fiscal 2026 revenue guidance of $480 million to $496 million, a range broadly in line with the roughly $486.3 million analyst consensus. The earnings call offered further management commentary on the outlook and recent developments. Artivion Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the adjusted profit, Artivion posted a GAAP net loss of $13.5 million, or $0.28 per share, compared with $0.24 in earnings per share a year earlier. The company’s low 2.55% net margin and elevated valuation could make the stock sensitive to any execution or profitability concerns. Artivion Q2 Earnings Meet Estimates

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.